Black Diamond Therapeutics Inc. (BDTX): Price and Financial Metrics


Black Diamond Therapeutics Inc. (BDTX): $3.00

-0.01 (-0.33%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BDTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

BDTX Stock Price Chart Interactive Chart >

Price chart for BDTX

BDTX Price/Volume Stats

Current price $3.00 52-week high $4.62
Prev. close $3.01 52-week low $1.18
Day low $2.99 Volume 58,884
Day high $3.14 Avg. volume 190,945
50-day MA $2.09 Dividend yield N/A
200-day MA $2.39 Market Cap 109.10M

Black Diamond Therapeutics Inc. (BDTX) Company Bio


Black Diamond Therapeutics, Inc. engages in the biotechnology company that discovers and develops therapeutic agents to target unique oncogenic protein-isoforms. The company was founded by Dr. David M. Epstein and Dr. Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.


BDTX Latest News Stream


Event/Time News Detail
Loading, please wait...

BDTX Latest Social Stream


Loading social stream, please wait...

View Full BDTX Social Stream

Latest BDTX News From Around the Web

Below are the latest news stories about BLACK DIAMOND THERAPEUTICS INC that investors may wish to consider to help them evaluate BDTX as an investment opportunity.

private equity firms who own 40% along with institutions invested in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) saw increase in their holdings value last week

A look at the shareholders of Black Diamond Therapeutics, Inc. ( NASDAQ:BDTX ) can tell us which group is most...

Yahoo | January 19, 2023

Black Diamond Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass. and NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing MasterKey therapies designed to overcome limitations of existing therapies by targeting families of oncogenic driver mutations in patients with genetically defined cancers, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update on the Company’s progress at the 41 st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 9:00 a.m. PT in San Francisco, California.

GlobeNewswire | January 5, 2023

Black Diamond Therapeutics Announces Changes to Board of Directors

CAMBRIDGE, Mass. and NEW YORK, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that Chairman of the Board of Directors, Robert (Bob) A. Ingram, has stepped down due to personal reasons. Existing Board member, Mark Velleca, M.D., Ph.D., has been appointed to succeed Mr. Ingram as the next Chairman. “Bob’s counsel, expertise and partnership have

Yahoo | December 19, 2022

Black Diamond rises 8% on spinout of Launchpad Therapeutics (NASDAQ:BDTX)

Black Diamond Therapeutics (BDTX) is trading ~8% higher premarket after the company said it had formed Launchpad Therapeutics, an antibody-focused precision oncology firm, with a…

Seeking Alpha | December 12, 2022

Black Diamond Therapeutics Announces Spinout of Launchpad Therapeutics, Inc., an Antibody-Focused Precision Oncology Company

- $30M Series A investment from Versant Ventures and NEA- CAMBRIDGE, Mass. and NEW YORK, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced the formation of Launchpad Therapeutics, Inc. (Launchpad), an antibody-focused precision oncology company, together with a $30 million Series A investment by founding investors, Versant Ventures and New Enterp

Yahoo | December 12, 2022

Read More 'BDTX' Stories Here

BDTX Price Returns

1-mo 66.67%
3-mo 31.58%
6-mo -14.29%
1-year -28.06%
3-year -92.00%
5-year N/A
YTD 66.67%
2022 -66.23%
2021 -83.37%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.622 seconds.